Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Compose a Response to This Article
Other responses
No responses have been published for this article.